ReviewOncoimmunology2013
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry.
Review in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma.Neurology(R) neuroimmunology & neuroinflammation · 2024Pooled it
- Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.Neurology(R) neuroimmunology & neuroinflammation · 2023Pooled it
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Trial
- Paraneoplastic Intracellular Neuropathies: A Narrative Review.Neurology and therapy · 2026Review
- The RNA-Binding Protein ELAVL4/HuD Promotes Stress-Associated Tumor Survival in Neuroendocrine Cancers.International journal of molecular sciences · 2026Review
- Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.Antibodies (Basel, Switzerland) · 2026Review
- Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors.Frontiers in immunology · 2025Article
- Sequential onset of anti-HU-related paraneoplastic sensory polyneuropathy and limbic encephalitis in pancreatic neuroendocrine tumour: a case report.Acta neurologica Belgica · 2024Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model.Cerebellum (London, England) · 2024Article
- Anti-GABAB receptor encephalitis: clinical and laboratory characteristics, imaging, treatments and prognosis.Frontiers in immunology · 2024Article
- Autoimmune Encephalitis-A Multifaceted Pathology.Biomedicines · 2023Article
- Effects of a Small-Molecule Perforin Inhibitor in a Mouse Model of CD8 T Cell-Mediated Neuroinflammation.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Four kinds of antibody positive paraneoplastic limbic encephalitis: A rare case report.World journal of clinical cases · 2023Article
- Article
- Single-Center Retrospective Analysis of Paraneoplastic Syndromes with Peripheral Nerve Damage.Brain sciences · 2022Article
- Autoimmune Encephalitis: A Physician's Guide to the Clinical Spectrum Diagnosis and Management.Brain sciences · 2022Review
- [Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint Inhibitor Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders.Journal of movement disorders · 2022Article
- Study on the pro-inflammatory mechanism of the HuD antibody in promoting M1 polarization and paraneoplastic neurological syndrome occurrence.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic neurological disorders (PNDs) are syndromes that develop in cancer patients when an efficient antitumor immune response, directed against antigens expressed by both malignant cells and healthy neurons, damages the nervous system. Herein, we analyze existing data on the mechanisms of loss of self tolerance and nervous tissue damage that underpin one of the most frequent PNDs, the anti-Hu syndrome. In addition, we discuss future directions and propose potential strategies aimed at blocking deleterious encephalitogenic immune responses while preserving the antineoplastic potential of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.